Increasing use of gonadotropin‐releasing hormone agonists for the treatment of localized prostate carcinoma

2005323 citationsReview

Authors

Vahakn B. Shahinian · The University of Texas Medical Branch at Galveston

Yong‐Fang Kuo · The University of Texas Medical Branch at Galveston

Jean L. Freeman · The University of Texas Medical Branch at Galveston

Eduardo Orihuela · The University of Texas Medical Branch at Galveston

James S. Goodwin · The University of Texas Medical Branch at Galveston

Abstract

The use of GnRH agonists for prostate carcinoma increased dramatically during the 1990s. This increase occurred across all stages and histologic grades of prostate carcinoma, and was greatest in patients >/= 80 years.

Topics & Keywords

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Urologic and reproductive health conditions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 103, Issue 8, pp. 1615-1624

DOI: 10.1002/cncr.20955

Field-Weighted Citation Impact: 12.21